Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

• Status: Withdrawn
• Trial end date: 2024-09-30

Summary

This research study is studying a combination of drugs as a possible treatment for multiple myeloma.

The drugs that will be administered are:

• ABI-009 (nab-rapamycin)

• Pomalidomide

• Dexamethasone

• Phase: Phase 1

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Aadi, LLC
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Everolimus; Pomalidomide; Sirolimus; Thalidomide